Anti-TGF-beta Therapy in Patients With Myelofibrosis



Status:Archived
Conditions:Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2011

Use our guide to learn which trials are right for you!

Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF)


TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with
myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and
myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The
investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the
fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation.
This is a noverl approach to the treatment of patients with myelofibrosis.



We found this trial at
2
sites
5777 E Mayo Blvd
Scottsdale, Arizona 85259
(480) 515-6296
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials